7 Podcast Episodes
Guselkumab Ranked Highest Overall in Skin Clearance with Philip Mease, MD
Guselkumab Ranked Highest Overall in Skin Clearance with Philip Mease, MD
Last week, Janssen announced results from a network meta-analysis (NMA) that showed that the biologic therapy guselkumab... Read more
31 Jan 2022
•
18mins
Rheumatology Author Prof Philip Mease: Upadacitinib in PsA
Rheumatology Author Prof Philip Mease: Upadacitinib in PsA
Professor Philip Mease from the University of Washington School of Medicine. Join Prof Peter Nash as he interviews notab... Read more
18 Jan 2021
•
24mins
Discussing the guidelines for managing psoriatic arthritis: Part 2 (Dafna Gladman, Philip Mease, and Oliver FitzGerald)
Discussing the guidelines for managing psoriatic arthritis: Part 2 (Dafna Gladman, Philip Mease, and Oliver FitzGerald)
In the second of a two-part series, Dafna Gladman, Philip Mease, and Oliver FitzGerald discuss the implications and limi... Read more
11 Mar 2020
•
11mins
Researcher comment: The DISCOVER-2 trial (with Philip Mease)
Researcher comment: The DISCOVER-2 trial (with Philip Mease)
Lead investigator Philip Mease outlines the results of the DISCOVER-2 trial, and discusses how guselkumab may impact the... Read more
11 Mar 2020
•
8mins
Discussing the guidelines for managing psoriatic arthritis: Part 1 (Dafna Gladman, Philip Mease, and Oliver FitzGerald)
Discussing the guidelines for managing psoriatic arthritis: Part 1 (Dafna Gladman, Philip Mease, and Oliver FitzGerald)
In the first of a two-part series, Dafna Gladman, Philip Mease, and Oliver FitzGerald discuss the development of the rec... Read more
30 Oct 2019
•
9mins
Researcher comment: The SPIRIT-H2H trial (with Philip Mease)
Researcher comment: The SPIRIT-H2H trial (with Philip Mease)
Lead investigator Philip Mease discusses the findings from the SPIRIT-H2H trial, a phase III head-to-head trial of ixeki... Read more
2 Jul 2019
•
7mins
Researcher comment: Tildrakizumab shows promise for PsA (with Philip Mease)
Researcher comment: Tildrakizumab shows promise for PsA (with Philip Mease)
Lead investigator Philip Mease outlines the results of a phase IIb trial supporting further development of the anti-inte... Read more
2 Jul 2019
•
8mins